Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women.

Abstract

BACKGROUND A new progestin-only, nondaily depot medroxyprogesterone acetate (DMPA) SC injectable contraceptive suspension (104 mg/0.65 mL) has been developed. Clinical trials (including dose-ranging, pharmacokinetic/pharmacodynamic, and contraceptive efficacy studies) indicating the effectiveness of this new formulation were conducted primarily in white… (More)

Topics

Cite this paper

@article{Toh2004SuppressionOO, title={Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women.}, author={Yeong Cheng Toh and John K. Jain and Mohamad H Rahnny and Frederick R Bode and Doug Ross}, journal={Clinical therapeutics}, year={2004}, volume={26 11}, pages={1845-54} }